Cipla’s wholly owned subsidiary -- Cipla USA, Inc is recalling over 400 cartons of generic anti-cancer medication, Nilotinib Capsules, due to a manufacturing issue. Cipla USA, Inc has recalled Nilotinib Capsules in two strengths (150 mg and 200 mg).
On February 18, 2026, Cipla USA, Inc had initiated the Class III voluntary recall. A Class III recall is initiated in a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Cipla is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: